Cristin-resultat-ID: 1722361
Sist endret: 4. oktober 2019, 09:45

Parenteral nutrition therapy in patients with incurable cancer: A retrospective medical chart review of current practice

  • Rikka Frøyen Sande
  • Lene Thoresen
  • Erik Torbjørn Løhre
  • Astrid Signe Nygard
  • Ørnulf Paulsen
  • Inger Ottestad
  • mfl.


Navn på arrangementet: 41st ESPEN Congress on Clinical Nutrition & Metabolism
Sted: Krakow
Dato fra: 31. august 2019
Dato til: 3. september 2019


Arrangørnavn: The European Society of Clinical nutrition and Metabolism

Om resultatet

Publiseringsår: 2019

Beskrivelse Beskrivelse


Parenteral nutrition therapy in patients with incurable cancer: A retrospective medical chart review of current practice


Rationale: Indication for use, dose and duration of parenteral nutrition (PN) in patients with incurable cancer is understudied. The aim of the study was to describe current practice of PN treatment in adult patients with incurable cancer at St. Olavs University Hospital, Trondheim, Norway. Methods: A retrospective medical chart review of patients with incurable cancer receiving PN between 2011 and 2017 was conducted. Of 271 identified patients, data from the first 78 patients was included in this preliminary analysis. Medical information was collected from start of PN until patients’ death. Results: The mean (SD) age was 63.5 (12.9) years, 41 women and 37 men. All patients received PN concomitant with anti-cancer treatment at some point in time. The most common indications for PN were “insufficient oral or enteral intake” (n=67) or “gastrointestinal malfunction” (n=17). At start of PN, there were no differences between subgroups in s-albumin, C-reactive protein level, metastatic disease, or ascites. The main reason for discontinuation of PN was imminently dying patient (n=36), patient preferences (n=19), and complications (n=12). The table presents available data on PN treatment and survival in subgroups defined by duration of PN treatment. Data presented as n or median (Q1-Q3). Variables 2 months P1 n Patients (n) 14 20 16 16 66 PN treatment Highest received PN dose, kcal 1100 (612-1600)#,¤ 1600 (1100-2200)# 1600 (1100-1600) 1750 (1450-2200)¤ 0.001 62 Received dose (percentage of estimated energy need) 73 (43-73) 78 (62-101) 69 (50-94) 97 (73-118) 0.03 52 Documented oral food intake, n 9 16 15 15 0.09 55 Survival From start of PN, days 19 (13-74)& 39 (26- 384) 61 (43-115) 168 (88-295)& 0.001 66 From PN termination, days 10 (4-70) 16 (5-358)§ 4.5 (1-70) 2 (1-7)§ 0.016 66 1Kruskal-Wallis test, Dunn’s Post Hoc test; # P=0.04, ¤ p=0.003, & P=0.001, § P=0.02 Conclusion: To our knowledge, this is the first study describing clinical practice with respect to dose, duration and termination of PN in incurable cancer patients. Preliminary data suggest that the use of PN was dynamic and differentiated. Termination of PN was based on expected patient survival, patient preferences, and treatment complications.


Intravenøs ernæringsbehandling til pasienter med uhelbredelig kreft


Rikka Frøyen Sande

  • Tilknyttet:

Britt Lene Thoresen

Bidragsyterens navn vises på dette resultatet som Lene Thoresen
  • Tilknyttet:
    ved Kreftklinikken ved St. Olavs Hospital HF

Erik T Løhre

Bidragsyterens navn vises på dette resultatet som Erik Torbjørn Løhre
  • Tilknyttet:
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet

Astrid Signe Nygard

  • Tilknyttet:
    ved Kirurgisk klinikk ved Sykehuset i Vestfold HF

Ørnulf Paulsen

  • Tilknyttet:
    ved Medisinsk klinikk ved Sykehuset Telemark HF
1 - 5 av 8 | Neste | Siste »